EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Advancing Lipid Management: Saudi Heart Association Position Statement on PCSK9-Targeted Therapies in the Primary and Secondary Prevention of Cardiovascular Disease

Waleed AlHabeeb, Hussein Alamri, Hussein Elbadawi, Yazed S AlRuthia, Waleed Alharbi, Owayed Alshammeri, Adel Tash, Shadi Almoziny, Naji Kholaif, Hussain Halawani, Fadia AlMahdi, Wael Yar und 1 weitere

Journal of the Saudi Heart Association · 18.05.2026 · 38 (1)

DOI: 10.37616/2212-5043.1488 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the Saudi Heart Association, online erschienen am 18.05.2026. Verfasst von Waleed AlHabeeb und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiac Sciences, King Saud University, Riyadh, Saudi Arabia. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite robust evidence for low-density lipoprotein cholesterol (LDL-C) reduction in atherosclerotic cardiovascular disease (ASCVD) prevention, attainment of guideline-recommended targets remains suboptimal in Saudi Arabia, especially among high- and very high-risk patients. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)-targeted therapies, which include monoclonal antibodies (evolocumab, alirocumab) and small interfering RNA (inclisiran), offer potent LDL-C lowering that can help address this gap.

Methods

The Saudi Heart Association (SHA) convened a multidisciplinary panel to review evidence from randomized controlled trials, real-world studies, and economic analyses on PCSK9-targeted therapies. Recommendations were developed through expert consensus, contextualized to the Saudi healthcare environment. Results and conclusions: PCSK9 inhibitors (evolocumab, alirocumab) lower LDL-C substantially by around 60% and reduce the risk of adverse cardiovascular outcomes when added to maximally tolerated statins. Inclisiran achieves similar LDL-C reductions with biannual dosing, potentially improving adherence, though cardiovascular outcome data are pending. Both drug classes are well tolerated across diverse patient populations, including those with high or very high-risk, familial hypercholesterolemia (FH), recent acute coronary syndrome (ACS), or statin intolerance. The SHA expert panel recommends the early integration of upfront combination treatment including PCSK9-targeted therapies for patients with high risk features unlikely to reach LDL-C goals with statins ± ezetimibe, including recent ACS, FH, established ASCVD, metabolic conditions with end-organ damage, and statin intolerance. For Saudi populations, targeted integration of these agents into combination regimens offers a significant opportunity to close LDL-C treatment gaps and reduce residual ASCVD risk.

Schlagwörter

Stichwörter der Autor:innen

Cardiovascular disease preventionInclisiranLipid-lowering therapyPCSK9 inhibitorsSaudi ArabiaStatin intolerance

Autor:innen und Institutionen

  • Department of Cardiac Sciences, King Saud University, Riyadh, Saudi Arabia.
  • Department of Cardiology, Prince Sultan Cardiac Centre, Riyadh, Saudi Arabia.
  • Metabolic Unit, My Clinic International, Jeddah, Saudi Arabia.
  • Pharmacoeconomics Research Unit, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
  • King Fahad Cardiac Center, King Saud University Medical City, Department of Cardiac Sciences, College of Medicine, King Saud University Riyadh, Saudi Arabia.
  • Department of Cardiology, Dr Sulaiman Alhabib - Al Rayyan Hospital, Riyadh, Saudi Arabia.

Zitieren

APA

AlHabeeb, W., Alamri, H., Elbadawi, H., AlRuthia, Y. S., Alharbi, W., Alshammeri, O., Tash, A., Almoziny, S., Kholaif, N., Halawani, H., AlMahdi, F., Yar, W., & Alhabib, K. F. (2026). Advancing Lipid Management: Saudi Heart Association Position Statement on PCSK9-Targeted Therapies in the Primary and Secondary Prevention of Cardiovascular Disease. Journal of the Saudi Heart Association, 38(1). https://doi.org/10.37616/2212-5043.1488

Vancouver

AlHabeeb W, Alamri H, Elbadawi H, AlRuthia YS, Alharbi W, Alshammeri O, et al. Advancing Lipid Management: Saudi Heart Association Position Statement on PCSK9-Targeted Therapies in the Primary and Secondary Prevention of Cardiovascular Disease. Journal of the Saudi Heart Association. 2026;38(1). doi:10.37616/2212-5043.1488

BibTeX
@article{AlHabeeb2026,
  author = {AlHabeeb, Waleed and Alamri, Hussein and Elbadawi, Hussein and AlRuthia, Yazed S and Alharbi, Waleed and Alshammeri, Owayed and Tash, Adel and Almoziny, Shadi and Kholaif, Naji and Halawani, Hussain and AlMahdi, Fadia and Yar, Wael and Alhabib, Khalid F},
  title = {Advancing Lipid Management: Saudi Heart Association Position Statement on PCSK9-Targeted Therapies in the Primary and Secondary Prevention of Cardiovascular Disease},
  journal = {Journal of the Saudi Heart Association},
  year = {2026},
  volume = {38},
  number = {1},
  doi = {10.37616/2212-5043.1488}
}
Kostenlos starten →